BioSpace News Archive

Moderna, Inc. announced business and clinical updates across its franchises and introduced several new development programs at the Company’s annual R&D Day.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to support World Sepsis Day today. World Sepsis Day is an initiative by the Global Sepsis Alliance and was established in 2012.

Avirmax Inc., Vice President of Research, Dr. Li Ou, and Associate Director of Operations, Ms. June Song , will attend the BioProcess International meeting in Boston between September 18th to 21st , 2023.

Dotmatics today announced the availability of the latest version of its Biology Solution, an end-to-end biologics data management and analysis tool designed to help R&D leaders get more insight from their data, faster.

Asieris Pharmaceuticals announced that the clinical trial of oral APL-1202 in combination with PD-1 inhibitor Tislelizumab as neoadjuvant therapy for muscular invasive bladder cancer (MIBC) completed the phase II interim analysis with positive results.

Sensei Biotherapeutics, Inc. today announced it will present additional preclinical data on SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held September 20 – 23, 2023 in Milan, Italy.

Q32 Bio and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the first patient has been dosed in a randomized, double-blind, placebo-controlled, Phase 2 multicenter, proof-of-concept study to evaluate bempikibart in adult patients with severe alopecia areata.

DalCor Pharmaceuticals announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration.

Poolbeg Pharma announces its unaudited interim results for the six months to 30 June 2023.

Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services.